18F-FDG PET/CT ist ein prognostischer biomarker bei patienten mit für brustkrebspatientinnen mit knochenmetastasen im vergleich zu18F-NaFPET/CT

Translated title of the contribution: 18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with18F-NaF PET/CT

A. Piccardo, M. Puntoni, S. Morbelli, Michela Massollo, F. Bongioanni, F. Paparo, V. Altrinetti, R. Gonella, A. Gennari, M. Iacozzi, G. Sambuceti, A. DeCensi

Research output: Contribution to journalArticle

Abstract

Aim: To compare18F-FDG PET/CT and18F-NaF PET/CT with respect to disease prognostication and outcome in patients affected by bone metastases from breast cancer (BC). Patients, methods: We retrospectively investigated 32 women with BC and documented bone metastases. Semi-quantitative parameters were applied to18F-FDG PET/CT and18F-Na PET/CT in order to evaluate disease extent and tumour metabolism. We used time-to-event analyses (Kaplan Meier and COX proportional hazard methods) to estimate progression-free (PFS) and overall survival (OS) in order to assess the independent prognostic value of18F-FDG PET/CT and18F-Na PET/CT. Results: The sensitivity of18F-NaF PET/CT (100%) was higher (p <0.05) than that of18F-FDG PET/CT (72% and 72%). None of the18F-FDG PET/CT-negative patients showed disease progression at the end of follow-up. After adjustment for age, Ki-67 levels, presence of visceral metastases, hormone therapy, duration of bone disease and response to first-line therapy, only18F-FDG SUV mean [HR 15.7, 95% confidence interval (CI) 1.15-214.5] and18F-FDG whole-body bone metabolic burden (WB-B-MB) (HR 16.9; 95%CI 1.87-152.2) were independently and significantly associated with OS. None of the18F-NaF PET/CT parameters were associated with OS. None of the conventional clinical prognostic parameters remained significantly associated with OS after the inclusion of PET/ CT parameters in the model. Conclusion:18F-FDG PET/CT is independently associated with OS in BC patients with bone metastases and its prognostic impact seems to be higher than conventional clinical and biological rognostic factors. Although18F-NaF PET/CT has a higher diagnostic sensitivity than18F-FDG PET/ CT, it is not independently associated with OS.

Original languageGerman
Pages (from-to)163-172
Number of pages10
JournalNuklearmedizin
Volume54
Issue number4
DOIs
Publication statusPublished - 2015

    Fingerprint

Keywords

  • F-FDG
  • F-NaF
  • Bone metastases
  • Breast cancer
  • PET/CT
  • Prognostic value

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Piccardo, A., Puntoni, M., Morbelli, S., Massollo, M., Bongioanni, F., Paparo, F., Altrinetti, V., Gonella, R., Gennari, A., Iacozzi, M., Sambuceti, G., & DeCensi, A. (2015). 18F-FDG PET/CT ist ein prognostischer biomarker bei patienten mit für brustkrebspatientinnen mit knochenmetastasen im vergleich zu18F-NaFPET/CT. Nuklearmedizin, 54(4), 163-172. https://doi.org/10.3413/Nukmed-0727-15-02